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reported approximately 20% impairment in productivity due to
psoriasis. Twenty-six percent of the patients indicated psoriasis
was the reason for altering their job type, description, or work
responsibilities. Thirty-four percent of patients believed that
their condition affected their choice of career or ability to ﬁnd a
job. Assuming patients were not paid during their absenteeism,
absence from work resulted in lost mean patient wages of
CDN$2580.97 per person per year. With an estimated 330,000
Canadians suffering from moderate to severe psoriasis, total lost
wages due to moderate to severe psoriasis may cost up to
approximately CDN$852 million for all moderate to severe pso-
riasis patients in Canada. CONCLUSION: The results of this
study indicate that moderate to severe psoriasis may have a
substantial impact on the work productivity of patients with this
disease. Further studies on lost productivity as well as societal
impact of moderate to severe psoriasis are needed.
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OBJECTIVE: To examine the effect of ustekinumab on work
productivity and the number of workdays missed due to pso-
riasis. METHODS: A total of 1995 patients were enrolled in the
PHOENIX I and II trials. Patients were randomized 1:1:1 to
one of three groups:placebo,ustekinumab 45mg,or ustekinumab
90mg.In the ustekinumab groups, patients received treatment at
weeks 0, 4, and every 12 weeks thereafter. Patients randomized
to placebo at baseline crossed-over to receive either 45 mg or
90 mg of ustekinumab at weeks 12, 16, and every 12 weeks
thereafter.Productivity was assessed using a 10cm Visual Analog
Scale (VAS), and change in productivity was recorded in cm
units. Productivity and number of workdays missed due to pso-
riasis in the last 4 weeks was evaluated at weeks 0 and 12 in
both trials. RESULTS: Mean and median baseline productivity
scores and number of workdays missed due to psoriasis were
similar between treatment groups at baseline. At week 12, the
ustekinumab 45 mg and 90 mg groups had signiﬁcantly greater
improvements(p < 0.001 for both comparisons)from baseline in
productivity scores than the placebo group.The mean (median)
change in productivity from baseline score at week 12 was –2.2
(-1.1) for the 45 mg group and –2.4 (-1.4) for the 90 mg
group, compared with 0.0(0.0) for the placebo group. The
mean(median)change from baseline to week 12 in the number
of workdays missed due to psoriasis in the last 4 weeks was 0.0
(0.0) in the placebo group, -0.2 (0.0) in the 45 mg group
(p < 0.002), and -0.3 (0.0) in the 90 mg group (p < 0.002).This
could translate to an annualized average reduction of missed
workdays due to psoriasis of 2.6 days for the 45 mg group and
3.9 days for the 90 mg group. CONCLUSION: Ustekinumab
45 mg and 90 mg resulted in signiﬁcantly improved productivity
compared with placebo in moderate-to-severe psoriasis patients,
as measured by the productivity VAS and workdays missed due
to psoriasis.
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OBJECTIVE: The loss of driving privileges in glaucoma patients
has a signiﬁcant impact on personal, social, and economic well-
being. As a result, glaucoma patients are believed to highly value
any intervention or pharmaceutical agent that can either preserve
or extend visual acuity. The objective of this study was to assess
the willingness to pay to maintain driving privileges in patients
with glaucoma. METHODS: A mailed survey assessing glau-
coma severity, current driving status and willingness to pay for
additional years of driving privileges was sent to a random
sample of 5,000 individuals. A contingent valuation scenario was
posed to individuals as “Your physician tells you that there is a
treatment available for glaucoma that will increase your chances
to see for a longer period of time, and thus maintain your ability
to drive independently. However, the treatment is not covered by
your insurer. If you had to make a decision today, what is the
maximum amount you would be willing to pay for the treatment
in order to maintain driving privileges for one more year?”
RESULTS: A total of 2,009 individuals completed the survey
for a 40% response rate. The majority of the responders were
women (70%) and the mean age of the population was 60.5
(SD = 16.5) years. Over 60% of individuals rated their glaucoma
as mild and 73% of individuals reported that they still drive.
Approximately 43% of responders replied that they would pay
up to $50,000 for one additional year of driving privileges.
CONCLUSION: Driving privileges and personal independence
are highly valued by older individuals. In order to maintain their
driving privileges and personal independence, older individuals
are willing to pay a substantial amount of money to improve
visual acuity.
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OBJECTIVES: Glaucoma is an optic neuropathy associated with
visual ﬁeld loss. Currently, treatment for glaucoma is focused on
controlling intraocular pressure. First-line treatment typically
involves â-blockers or prostaglandin analogs (PAs). â-blockers
and other intraocular pressure lowering agents (IOPLAs) may be
used as adjunctive therapy to prostaglandins. We quantiﬁed the
use of adjunctive therapy in association with prostaglandins.
METHODS: We conducted a cohort study using pharmacy
dispensing data from The Netherlands using the PHARMO
database. We identiﬁed all patients with a ﬁrst dispensing for
bimatoprost, latanoprost or travoprost between January 2, 1998
and July 1, 2006, and determined the proportions of patients
who received adjunctive therapy in the ﬁrst 12 months of pros-
taglandin use. Use of adjunctive therapy was identiﬁed by at least
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